MMP2 as an independent prognostic stratifier in oral cavity cancers.
Biomarker
Head and Neck
Metalloproteinase
Oral cavity
Prognosis
Secretome
Squamous cell carcinoma
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
13 05 2020
13 05 2020
Historique:
entrez:
16
9
2020
pubmed:
17
9
2020
medline:
17
9
2020
Statut:
epublish
Résumé
Around 25% of oral cavity squamous cell carcinoma (OCSCC) are not controlled by the standard of care, but there is currently no validated biomarker to identify those patients. Our objective was to determine a robust biomarker for severe OCSCC, using a biology-driven strategy. Tumor and juxtatumor secretome were analyzed in a prospective discovery cohort of 37 OCSCC treated by primary surgery. Independent biomarker validation was performed by RTqPCR in a retrospective cohort of 145 patients with similar clinical features. An 18-gene signature (18 G) predictive of the response to PD-1 blockade was evaluated in the same cohort. Among 29 deregulated molecules identified in a secretome analysis, including chemokines, cytokines, growth factors, and molecules related to tumor growth and tissue remodeling, only soluble MMP2 was a prognostic biomarker. In our validation cohort, high levels of High levels of MMP2 were an independent and validated prognostic biomarker, surpassing other molecules of a large panel of the tumor and immune-related processes, which may be used to select poor prognosis patients for intensified neoadjuvant or adjuvant regimens.
Sections du résumé
Background
Around 25% of oral cavity squamous cell carcinoma (OCSCC) are not controlled by the standard of care, but there is currently no validated biomarker to identify those patients. Our objective was to determine a robust biomarker for severe OCSCC, using a biology-driven strategy.
Patients and methods
Tumor and juxtatumor secretome were analyzed in a prospective discovery cohort of 37 OCSCC treated by primary surgery. Independent biomarker validation was performed by RTqPCR in a retrospective cohort of 145 patients with similar clinical features. An 18-gene signature (18 G) predictive of the response to PD-1 blockade was evaluated in the same cohort.
Results
Among 29 deregulated molecules identified in a secretome analysis, including chemokines, cytokines, growth factors, and molecules related to tumor growth and tissue remodeling, only soluble MMP2 was a prognostic biomarker. In our validation cohort, high levels of
Conclusion
High levels of MMP2 were an independent and validated prognostic biomarker, surpassing other molecules of a large panel of the tumor and immune-related processes, which may be used to select poor prognosis patients for intensified neoadjuvant or adjuvant regimens.
Identifiants
pubmed: 32934875
doi: 10.1080/2162402X.2020.1754094
pii: 1754094
pmc: PMC7466851
doi:
Substances chimiques
B7 Antigens
0
CD276 protein, human
0
FUT4 protein, human
EC 2.4.1.-
Fucosyltransferases
EC 2.4.1.-
MMP2 protein, human
EC 3.4.24.24
Matrix Metalloproteinase 2
EC 3.4.24.24
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
1754094Informations de copyright
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
The authors declare no potential conflicts of interest.
Références
Nature. 1994 Jul 7;370(6484):61-5
pubmed: 8015608
Clin Cancer Res. 2013 Mar 1;19(5):1169-79
pubmed: 23349315
J Exp Med. 1992 Jul 1;176(1):59-65
pubmed: 1613466
Cancer Cell. 2011 Mar 8;19(3):333-46
pubmed: 21397857
Front Immunol. 2017 Mar 08;8:205
pubmed: 28337194
J Biol Chem. 2017 Oct 27;292(43):17963-17974
pubmed: 28860188
JCO Precis Oncol. 2018;2018:
pubmed: 29862382
JAMA Otolaryngol Head Neck Surg. 2017 Jul 1;143(7):685-690
pubmed: 28448645
Oncoimmunology. 2017 Aug 9;6(11):e1356148
pubmed: 29147608
J Natl Cancer Inst. 2004 Nov 17;96(22):1714-7
pubmed: 15547184
Front Oncol. 2019 May 31;9:434
pubmed: 31214495
In Vivo. 2008 Sep-Oct;22(5):593-7
pubmed: 18853752
Blood. 2002 Aug 15;100(4):1160-7
pubmed: 12149192
Head Neck. 2017 Sep;39(9):1845-1853
pubmed: 28640483
J Exp Med. 2005 Jul 4;202(1):61-72
pubmed: 15998788
J Leukoc Biol. 2006 Dec;80(6):1434-44
pubmed: 16980511
J Immunol. 2007 Feb 15;178(4):2278-86
pubmed: 17277133
ANZ J Surg. 2015 Nov;85(11):843-8
pubmed: 24171785
Oncogene. 2009 Jul 30;28(30):2723-37
pubmed: 19525975
J Oral Pathol Med. 2015 May;44(5):345-52
pubmed: 25212455
Biochim Biophys Acta. 2013 Nov;1834(11):2259-70
pubmed: 23416532
Cell. 2010 Apr 2;141(1):52-67
pubmed: 20371345
Head Neck. 2006 Feb;28(2):107-13
pubmed: 16388526
Clin Proteomics. 2010 Sep;6(3):75-82
pubmed: 20930922
Head Neck. 2016 Apr;38 Suppl 1:E747-53
pubmed: 25900716
Int J Gynecol Cancer. 2012 Oct;22(8):1303-9
pubmed: 22964525
J Exp Clin Cancer Res. 2012 Oct 29;31:90
pubmed: 23107277
Clin Cancer Res. 2004 Jan 15;10(2):634-40
pubmed: 14760086
J Biol Chem. 1994 Jun 3;269(22):15918-24
pubmed: 8195247
Ann Oncol. 2014 Feb;25(2):462-6
pubmed: 24401930
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
J Oral Maxillofac Surg. 2006 Sep;64(9):1409-14
pubmed: 16916677
BMC Cancer. 2015 Jun 05;15:456
pubmed: 26043921
Nucleic Acids Res. 2009 Jan;37(Database issue):D907-12
pubmed: 18978022
Cancer. 2008 Jan 1;112(1):94-103
pubmed: 18022917
Lancet. 2008 May 17;371(9625):1695-709
pubmed: 18486742
Science. 2018 Oct 12;362(6411):
pubmed: 30309915
Mod Pathol. 2006 Feb;19(2):208-17
pubmed: 16424893
Expert Opin Drug Discov. 2018 Jan;13(1):75-87
pubmed: 29088927
Cell. 2017 Dec 14;171(7):1611-1624.e24
pubmed: 29198524
Biochim Biophys Acta Mol Cell Res. 2017 Nov;1864(11 Pt A):2043-2055
pubmed: 28526562
Eur Arch Otorhinolaryngol. 2016 Dec;273(12):4417-4424
pubmed: 27188507
J Clin Oncol. 2015 Oct 10;33(29):3305-13
pubmed: 26351341
Oral Oncol. 2017 Sep;72:38-47
pubmed: 28797460
J Immunol. 1996 Jan 1;156(1):1-4
pubmed: 8598448
BMC Cancer. 2018 May 22;18(1):579
pubmed: 29783929
Int J Oncol. 2003 Apr;22(4):891-8
pubmed: 12632084
BMC Cancer. 2019 Jun 14;19(1):581
pubmed: 31200666
J Clin Oncol. 2008 Dec 1;26(34):5518-23
pubmed: 18936479